Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Current Deferred Revenue (2020 - 2025)

Rani Therapeutics Holdings has reported Current Deferred Revenue over the past 3 years, most recently at $8.5 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $8.5 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $8.5 million (changed N/A YoY), and the annual figure for FY2025 was $8.5 million, changed.
  • Current Deferred Revenue for Q4 2025 was $8.5 million at Rani Therapeutics Holdings, up from $600000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RANI hit a ceiling of $8.5 million in Q4 2025 and a floor of $600000.0 in Q3 2024.